The Beijing Medicine and Medical Device Innovation Service Station (Beijing E-Town Station) was unveiled on May 29. 

Officials from the National Medical Products Administration, Beijing Municipal Medical Products Administration and Beijing E-Town as well as company representatives attended the unveiling ceremony. 

Qu Haopeng, deputy director of the Beijing Municipal Medical Products Administration (BMPA), pointed out that the BMPA will work together with Beijing E-Town to optimize the business environment, build a multi-channel, multi-level enterprise service channel, promote institutional innovation in the industry, and open up the industrial chain, striving to create a globally influential highland for medical industry innovation.

Shen Yonggang, deputy director of the Beijing E-Town, said Beijing E-Town will support the construction and operation of the innovation service station, offer services close to the enterprises, and provide more guarantees for innovative products.

The office of the Beijing Medicine and Medical Device Innovation Service Station (Beijing E-Town Station) is located on the 1st floor of Yicheng International Center, and the service hours are from 9:30 am to 5:00 pm on weekdays. 

Focusing on serving enterprises, the service station will provide a one-stop service including personnel training, customized consulting, pre-evaluation services, research projects, platform construction, and brand building, covering 12 work contents in six aspects for biopharmaceutical companies in Beijing, especially in the southern region.

Biotechnology and the big health industry, as one of the four leading industries in Beijing E-Town, cover more than 3,500 companies in various sub-sectors such as medicines, devices, and services. 

It spans the entire industry chain of innovative research and development, clinical services, large-scale production, commercial distribution, and terminal applications, and has accumulated a solid foundation for industrial development. 

After the station is put into use, it will strengthen the service and guidance for innovative medical device projects, accelerate the research and development, maximize the benefits of policies, and improve the ecosystem of the biopharmaceutical industry.